Meryl Zausner has more than 35 years of experience developing and launching innovative business units in the pharmaceutical and consumer product industry.
Previously, Meryl served as chief financial and administrative officer of Novartis Pharmaceuticals Inc. in the U.S., and a member of the Pharmaceutical Executive Committee and Global Finance Leadership Team. In her time with Novartis, she was instrumental in the launch of the Oncology Business Unit, as well as the company’s shared services organization. Meryl was a member of the Novartis Global Oncology leadership team and played a key role in developing and commercializing blockbuster therapies including Gleevec® (imatinib).
Meryl currently is a board member and chair of the audit committee of the Multiple Myeloma Research Foundation, and board member of Deirdre’s House, an advocacy center for children who are victims of abuse or neglect. She also serves on the board of Seres Therapeutics, Inc.